Licensing Arrangements (Details) £ in Millions	1 Months Ended	3 Months Ended		8 Months Ended	9 Months Ended
	Jan. 29, 2021 USD ($)	Sep. 30, 2021 USD ($) $ / £	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($) $ / £	Sep. 30, 2021 USD ($) $ / £	Sep. 30, 2021 GBP (£) $ / £	Mar. 31, 2019 USD ($) $ / £	Mar. 31, 2019 GBP (£) $ / £	Jan. 31, 2019 USD ($) $ / £	Jan. 31, 2019 GBP (£) $ / £	Dec. 31, 2015 USD ($) $ / £	Dec. 31, 2015 GBP (£) $ / £
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Foreign currency exchange rate, translation | $ / £		0.74		0.74	0.74	0.74	0.86	0.86	0.74	0.74	0.74	0.74
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense		$ 0	$ 0	$ 0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Z Factor
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and regulatory milestone payments											$ 500,000	£ 0.4
Research and development expense	$ 0	0	$ 0	0	$ 0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Morphogen-LX
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and regulatory milestone payments											$ 1,100,000	£ 0.8
Research and development expense	$ 0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Palladio
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense				0
Maximum contingent consideration payment		32,500,000		32,500,000	32,500,000
Maximum aggregate commercial milestone payments		16,300,000		16,300,000	16,300,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Palladio | Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments		19,000,000		19,000,000	19,000,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | ApcinteX
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense				0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | ApcinteX | CE
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and regulatory milestone payments		900,000		900,000	900,000	£ 0.7
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Pega-One | Roche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and regulatory milestone payments		16,000,000		16,000,000	16,000,000
Maximum aggregate commercial milestone payments		125,000,000		125,000,000	125,000,000
Upfront payment		2,000,000		2,000,000	$ 2,000,000
Minimum percent of consideration due to counterparty					10.00%
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Janpix Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and commercial milestone payments		30,000,000		30,000,000	$ 30,000,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Capella Biosciences Limited | Lonza Sales AG
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense		42,060		116,960
Maximum aggregate development and commercial milestone payments		5,400,000		5,400,000	5,400,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | PearlRiver Bio GmbH | LDC | PearlRiver Bio GmbH License Agreement with Lead Discovery Center GmbH for Exon20
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and regulatory milestone payments							$ 31,400,000	£ 27.0
Maximum aggregate commercial milestone payments							17,400,000	15.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | PearlRiver Bio GmbH | LDC | PearlRiver Bio GmbH License Agreement with Lead Discovery Center GmbH for C797
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and regulatory milestone payments							9,100,000	7.8
Maximum aggregate commercial milestone payments							$ 11,600,000	£ 10.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Orexia | X-Chem
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and regulatory milestone payments		24,800,000		24,800,000	24,800,000
Maximum aggregate commercial milestone payments		60,000,000		60,000,000	60,000,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Orexia | Heptares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and regulatory milestone payments									$ 17,000,000	£ 12.6
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Inexia | Heptares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and regulatory milestone payments									$ 16,400,000	£ 12.1
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Inexia | OptiNose
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum aggregate development and regulatory milestone payments		8,000,000		8,000,000	8,000,000
Maximum aggregate commercial milestone payments		$ 37,000,000		$ 37,000,000	$ 37,000,000